Lv71
4970 积分 2023-02-07 加入
A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update
3小时前
已完结
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
3小时前
已完结
T-cell co-stimulation through the CD2 and CD28 co-receptors induces distinct signalling responses
7小时前
已完结
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
7小时前
已完结
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy
13天前
已完结
A novel, label‐free, pre‐equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells
1个月前
已完结
Binding affinity determination of therapeutic antibodies to membrane protein targets: Kinetic Exclusion Assay using cellular membranes for anti-CD20 antibody
1个月前
已完结
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy
1个月前
已完结
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
1个月前
已完结
The blood–tumour barrier in cancer biology and therapy
1个月前
已完结
皖公网安备34019202002308
